Aflibercept 24-Month Outcomes in Diabetic Macular Edema With and Without Prior Macular Laser Therapy: Data from the Fight Retinal Blindness! Registry

Macular Diseases

Outcomes of eyes with persistent diabetic macular oedema: The Fight Retinal Blindness! Project

Br J Ophthalmol

Fraser-Bell S, Lee NS, Hashimoto Y, Pollreisz A, Witmer A, Viola F, Lavid FJ, Steiner H, Gabrielle PH, Barry R, Silva R, Barthelmes D, Gillies MC

doi: 10.1136/bjo-2025-328621

Macular Diseases

Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report

Ophthalmol Sci

Spindler J, Artemiev D, Pfister IB, Schild C, Tillmann A, Heck K, Gabathuler F, Ruscitti L, Spitznagel T, Kitsos-Kalyvianakis K, Munk MR, Hatz K, Zweifel SA, Grimaldi G, Somfai GM, Ambresin A, Weinberger A, Eandi CM, Feltgen N, Kitay A, Ebneter A, Garweg JG

doi: 10.1016/j.xops.2026.101087

Macular Diseases

Twelve-Month Outcomes of Brolucizumab in Routine Clinical Practice: Fight Retinal Blindness! Registry

Clin Exp Ophthalmol

Dang TM, Invernizzi A, Nguyen V, Hashimoto Y, Romano F, Cozzi M, Arnold J, Wong J, Mehta H, Fraser-Bell S, Barry R, Barthelmes D, Gillies M, Luckie A

doi: 10.1111/ceo.70033

Macular Diseases

Twelve-Month Outcomes of Anti-VEGF Therapy for nAMD with Brolucizumab, Aflibercept, and Ranibizumab in the Polish National Registry: A Multicenter Database Study

J Clin Med

Teper S, Ledwoń D, Romaniszyn-Kania P, Sendecki A, Tuszy A, Nycz J, Mitas AW, Figurska M, Wylęgała E, Rękas M

doi: 10.3390/jcm14196771

Macular DiseasesRetinal Diseases

Six-Month Real-World Data in Macular Edema Due to Retinal Vein Occlusion Treated with Faricimab: Swiss Retina Research Network Report

Ophthalmol Ther

Heck K, Hatz K, Cattaneo M, Pfister I, Magnin S, Ruscitti L, Stasik I, Tillmann A, Shamshiev M, Fang J, Weinberger A, Zweifel SA, Garweg JG, Eandi CM, Grimaldi G, Munk MR, Somfai GM, Ambresin A, Feltgen N

doi: 10.1007/s40123-026-01442-w

Macular Diseases

Assessment of real-life visual outcomes and treatment efficacy of diabetic macular edema in patients with type 2 diabetes

BMC Ophthalmol

Konttinen A, Wirkkala J, Kubin AM, Ohtonen P, Hautala N

doi: 10.1186/s12886-026-05083-2

Macular Diseases

Real-World Outcomes in Neovascular AMD with Visit Gaps under Anti-VEGF Therapy: Data from the FRB! Registry

Ophthalmol Retina

Goncalves L, Hashimoto Y, Barthelmes D, Barry R, Pollreisz A, Wolff B, Toole LO, Ponsioen TL, Morros HB, Creuzot-Garcher C, Gillies M, Gabrielle PH

doi: 10.1016/j.oret.2026.04.007

Macular Diseases

Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: 96-Week Results from the Randomized Phase 2/3 PHOTON Trial

Ophthalmology

Do DV, Wykoff CC, Sivaprasad S, Brown DM, Boyer DS, Sakamoto T, Win P, Joshi S, Salehi-Had H, Seres A, Berliner AJ, Leal S, Vitti R, Chu KW, Reed K, Cheng Y, Bhore R, Bai Z, Schmidt-Ott U, Schmelter T, Schulze A, Hasanbasic Z, Morgan-Warren PJ, Zhang X, Hirshberg B, Yancopoulos GD, PHOTON investigators

doi: 10.1016/j.ophtha.2025.10.028

Macular Diseases

Real-world early outcomes of intravitreal faricimab 6-mg and aflibercept 2-mg injection in diabetic macular oedema

Br J Ophthalmol

Chalkiadaki E, Sim YS, Williams O, Elder L, Addison PK, Hamilton RD, Nicholson L, Sivaprasad S, Heng LZ

doi: 10.1136/bjo-2025-328893

Related content

Outcomes of eyes with persistent diabetic macular oedema: The Fight Retinal Blindness! Project

Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report

Twelve-Month Outcomes of Brolucizumab in Routine Clinical Practice: Fight Retinal Blindness! Registry

Twelve-Month Outcomes of Anti-VEGF Therapy for nAMD with Brolucizumab, Aflibercept, and Ranibizumab in the Polish National Registry: A Multicenter Database Study

Six-Month Real-World Data in Macular Edema Due to Retinal Vein Occlusion Treated with Faricimab: Swiss Retina Research Network Report

Assessment of real-life visual outcomes and treatment efficacy of diabetic macular edema in patients with type 2 diabetes

Real-World Outcomes in Neovascular AMD with Visit Gaps under Anti-VEGF Therapy: Data from the FRB! Registry

Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: 96-Week Results from the Randomized Phase 2/3 PHOTON Trial

Real-world early outcomes of intravitreal faricimab 6-mg and aflibercept 2-mg injection in diabetic macular oedema